Healthcare / BiotechnologyNYSE
$22.17
-1.06 (-4.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-67.5M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$799M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-33.5%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+85.7%
FCF CAGR
—
FCF margin
-589.8%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.0M · net income $-68.9M · FCF $-76.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $13.0M | $13.0M | $7.0M |
| Net Income | $-68.9M | $-68.9M | $-66.8M |
| EBITDA | $-79.7M | $-79.7M | $-69.5M |
| EPS | — | — | -45.29 |
| Operating Margin | -623.6% | -623.6% | -1000.2% |
| Net Margin | -529.8% | -529.8% | -954.4% |
| Balance Sheet | |||
| Debt/Equity | 0.01 | 0.01 | — |
| Current Ratio | 20.36 | 20.36 | — |
| Cash Flow | |||
| Free Cash Flow | $-76.7M | $-76.7M | $-58.3M |
| Returns | |||
| ROE | -33.5% | -33.5% | 46.3% |
| Valuation | |||
| P/B | 3.40 | 3.40 | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-45.29 → n/d
Residual
+9.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.